Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
7.68
-0.44 (-5.42%)
Nov 18, 2024, 12:55 PM EST - Market open
Company Description
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders.
Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Camp4 Therapeutics Corporation
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Joshua Mandel-Brehm |
Contact Details
Address: One Kendall Square, Building 1400 West Cambridge, Massachusetts 02139 United States | |
| Phone | (617) 651-8867 |
| Website | camp4tx.com |
Stock Details
| Ticker Symbol | CAMP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001736730 |
| CUSIP Number | 128126109 |
| ISIN Number | US1281262089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Josh Mandel-Brehm | President, Chief Executive Officer and Director |
| David Bumcrot, PhD | Chief Scientific Officer |
| Kelly Gold | Chief Financial Officer |
| Yuri Maricich | Chief Medical Officer |
| Steven Holtzman | Chair of the Board of Directors |
| James Boylan | Director |
| Jorge Conde | Director |
| Ingo Chakravarty | Director |
| Michael Higgins | Director |
| Amir Nashat, ScD | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 424B4 | Prospectus |
| Oct 10, 2024 | EFFECT | Notice of Effectiveness |
| Oct 10, 2024 | CERT | Certification by an exchange approving securities for listing |